Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Equity Average (2016 - 2025)

Vanda Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $396.6 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 26.54% to $396.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $396.6 million, a 26.54% decrease, with the full-year FY2025 number at $432.9 million, down 20.1% from a year prior.
  • Equity Average hit $396.6 million in Q4 2025 for Vanda Pharmaceuticals, down from $476.2 million in the prior quarter.
  • Over the last five years, Equity Average for VNDA hit a ceiling of $544.5 million in Q1 2024 and a floor of $396.6 million in Q4 2025.
  • Historically, Equity Average has averaged $509.2 million across 5 years, with a median of $516.8 million in 2022.
  • Biggest five-year swings in Equity Average: grew 11.9% in 2021 and later fell 26.54% in 2025.
  • Tracing VNDA's Equity Average over 5 years: stood at $499.1 million in 2021, then rose by 4.47% to $521.4 million in 2022, then grew by 4.33% to $544.0 million in 2023, then dropped by 0.76% to $539.9 million in 2024, then fell by 26.54% to $396.6 million in 2025.
  • Business Quant data shows Equity Average for VNDA at $396.6 million in Q4 2025, $476.2 million in Q3 2025, and $498.9 million in Q2 2025.